Research Paper Volume 15, Issue 18 pp 9464—9478

Serum sirtuin1: a potential blood biomarker for early diagnosis of Alzheimer’s disease

Jia Wang1,3, *, , Fang Zhou2, *, , Chang-E Xiong1,3, *, , Gui-Ping Wang1,3, , Lin-Wanyue Chen1,3, , Yu-Tong Zhang4, , Shi-Ge Qi4, , Zhi-Hui Wang4, , Can Mei1,3, , Yu-Jia Xu1,3, , Jian-Bo Zhan2, , Jing Cheng1,3, ,

  • 1 School of Public Health, Wuhan University of Science and Technology, Wuhan 430065, Hubei, China
  • 2 Hubei Provincial Center for Disease Control and Prevention, Wuhan 430079, Hubei, China
  • 3 Hubei Province Key Laboratory of Occupational Hazard Identification and Control, Wuhan University of Science and Technology, Wuhan 430065, Hubei, China
  • 4 Chinese Center for Disease Control and Prevention, Beijing 102206, China
* Equal contribution

Received: May 1, 2023       Accepted: August 20, 2023       Published: September 22, 2023
How to Cite

Copyright: © 2023 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: Sirtuin 1, a nicotinamide adenine dinucleotide-dependent deacetylase that is highly expressed in the hippocampus and anterior cortex tissues related to Alzheimer’s Disease pathology, can cross the blood-brain barrier and is a promising biomarker.

Methods: A 1:1:1 case-control study was conducted and serum fasting blood glucose, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, SIRT1, IL-6, Aβ1-42, T-tau and P-tau-181 levels were evaluated in blood samples of 26 patients form the Alzheimer’s Disease group, 26 patients form the mild cognitive impairment group, and 26 individuals form the normal control group. Receiver operator characteristic curves were used to evaluate the diagnostic significance.

Results: Serum SIRT1 level was significantly down-regulated in the mild cognitive impairment patients and Alzheimer’s Disease patients compared with that in the normal control group (P<0.05). ROC curve analysis demonstrated that SIRT1 was a promising biomarker to distinguish Alzheimer’s Disease patients from the mild cognitive impairment patients and the normal control group. In addition, SIRT1 was estimated to perform well in the diagnosis of Alzheimer’s Disease ([AUC] = 0.742).

Conclusions: In summary, the present study suggested that serum SIRT1 might be an early promising diagnostic biomarker for Alzheimer’s Disease.


AD: Alzheimer’s Disease; MCI: Mild Cognitive Impairment; NC: Normal Control; MMSE: Mini-Mental State Examination; ADL: Activities of Daily Living; NIA-AA: National Institute on Aging-Alzheimer’s Association; GDS: Geriatric Depression Scale; HIS: Hachinski Ischemic Score; CDR: Clinical Dementia Rating; CT: computed tomography; Mean±SD: mean± standard deviation; OR: odds ratio; CI: confidence interval; ROC: receiver operator characteristic curve; AUC: Area under the ROC curve; Se: sensitivity; Sp: specificity; ELISA: Enzyme Linked Immunosorbent Assay; CSF: Cerebrospinal Fluid; MoCA: Montreal Cognitive Assessment; VD: Vascular dementia; PD: Parkinson’s disease; BMI: body mass index; FBG: fasting blood glucose; L-LDL: Low-density lipoprotein cholesterol; H-LDL: High-density lipoprotein cholesterol; TC: total cholesterol; TG: triglyceride.